Department of Dermatology
Medical Center – University of Freiburg
Hauptstrasse 7
79104 Freiburg i. Brsg.
- +49 (0) 761/ 270 – 67850
- alexander.nystroem@uniklinik-freiburg.de
- Homepage
Current position
Group leader, Department of Dermatology, Medical Center – University of Freiburg
Academic training
| 1997 – 2002 | Study of Molecular Biology at Lund University, Lund, Sweden |
Scientific qualifications
| 2024 | Habilitation in Experimental Dermatology, University of Freiburg |
| 2006 | Dissertation in Developmental Biology, Lund University, Sweden |
Postgraduate Positions
| since 2013 | Group leader, Department of Dermatology, Medical Center - University of Freiburg |
| 2010 – 2012 | Postdoctorate, Department of Dermatology, Medical Center - University of Freiburg |
| 2007 – 2009 | Postdoctorate, Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA |
Miscellaneous (Honors, Awards)
| 2021 - 2022 | Internal Senior Fellow – Freiburg Institute for Advanced Studies |
| 2016 | Rupert Timpl Award International Society For Matrix Biology |
link to all publications from A. Nyström: Pubmed
Publications based on CRC1160 funding
Kiritsi D, Schauer F, Gewert S, Reineker K, Reimer-Taschenbrecker A, Schwieger-Briel A, Ott H, Schmoor C, Grishina O, Murrell D, Stiller B, Zahn T, Nyström A, Bruckner-Tuderman L. 2024. Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. EClinicalMedicine. 2024 Oct 30;77:102900. doi: 10.1016/j.eclinm.2024.102900.
Conradt G, Hausser I, Nyström A. 2024. Epidermal or Dermal Collagen VII Is Sufficient for Skin Integrity: Insights to Anchoring Fibril Homeostasis. J Invest Dermatol. 2024 Jun;144(6):1301-1310.e7. doi: 10.1016/j.jid.2023.11.003.
Zeyer KA, Bornert O, Nelea V, Bao X, Leytens A, Sharoyan S, Sengle G, Antonyan A, Bruckner-Tuderman L, Dengjel J, Reinhardt DP, Nyström A. 2024. Dipeptidyl peptidase-4-mediated fibronectin processing evokes a pro-fibrotic extracellular matrix. J Invest Dermatol. S0022-202X(24)00260-4. doi: 10.1016/j.jid.2024.03.020.
Conradt G, Hausser I, Nyström A. 2023. Epidermal or Dermal Collagen VII Is Sufficient for Skin Integrity: Insights to Anchoring Fibril Homeostasis. J Invest Dermatol. 2023 Nov 24:S0022-202X(23)03102-0. doi: 10.1016/j.jid.2023.11.003.
Lehr, S., F. Felber, I. Tantcheva-Poor, C. Kessler, R. Eming, A. Nystrom, M. Rizzi, and D. Kiritsi. 2022. Occurrence of autoantibodies against skin proteins in patients with hereditary epidermolysis bullosa predisposes to development of autoimmune blistering disease. Front Immunol 13: 945176. doi: 10.3389/fimmu.2022.945176.
Susana Minguet, Alexander Nyström, Dimitra Kiritsi, Marta Rizzi. 2022. Inborn errors of immunity and immunodeficiencies: Antibody-mediated pathology and autoimmunity as a consequence of impaired immune reactions. Eur J Immunol, First published: 20 April 2022; doi.org/10.1002/eji.202149529
Schauer F, Nyström A, Kunz M, Hübner S, Scholl S, Athanasiou I, Alter S, Fischer J, Has C, Kiritsi D. 2022. Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita. Front Immunol. 13:883967. doi: 10.3389/fimmu.2022.883967.
Flum, M., S. Dicks, Y. H. Teng, M. Schrempp, A. Nystrom, M. Boerries, and A. Hecht. 2022. Canonical TGFbeta signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT. Oncogene. pii: 10.1038/s41388-022-02190-4. doi: 10.1038/s41388-022-02190-4.
Nyström A, Bruckner-Tuderman L, Kiritsi D. 2021. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet. 12:737272. doi: 10.3389/fgene.2021.737272. eCollection 2021.
Bernasconi R, Thriene K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth A-C, Stumpe M, Kiritsi D, Martin SF, Hinz B, Bruckner-Tuderman L, Dengjel J, Nyström A. 2021. Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7). EMBO Mol Med. e14392.
Akasaka E, Kleiser S, Sengle G, Bruckner-Tuderman L, Nyström A. 2020. Diversity of Mechanisms Underlying Latent TGF-β Activation in Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. S0022-202X(20)32357-5. doi: 10.1016/j.jid.2020.10.024. Online ahead of print.
Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. 2020. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J Invest Dermatol. S0022-202X(20)32061-3. doi: 10.1016/j.jid.2020.08.018. Online ahead of print.
Nyström A, Kiritsi D. 2020. Transmembrane collagens – unexplored mediators of epidermal-dermal communication and tissue homeostasis. Exp Dermatol. doi: 10.1111/exd.14180. Online ahead of print.
Nauroy, P., and A. Nystrom. 2020. Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease. Matrix Biol Plus 6-7: 100019.
Bornert, O., T. Kocher, C. Gretzmeier, B. Liemberger, S. Hainzl, U. Koller, and A. Nystrom. 2019. Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies. Matrix Biol Plus 4: 100017.
